P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS

Eitemau Tebyg

• Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
  gan: Ja Min Byun, et al.
  Cyhoeddwyd: (2022-10-01)
• Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
  gan: Cristina Gasparetto, et al.
  Cyhoeddwyd: (2021-02-01)
• The Novel Inhibitory Effect of YM976 on Adipocyte Differentiation
  gan: Hee Jung Kim, et al.
  Cyhoeddwyd: (2023-01-01)
• Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study
  gan: Ji Hyun Lee, et al.
  Cyhoeddwyd: (2024-06-01)
• Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
  gan: Hyungwoo Cho, et al.
  Cyhoeddwyd: (2024-01-01)